Meissa Appoints Robert Walker, M.D., Chief Medical Officer

Science: Scent of a Vaccine

National Geographic: A Spritz Instead of a Jab? Future COVID-19 Vaccines May Go up Your Nose.

Reuters: Intranasal Vaccine Aims to Block Virus at Point of Entry

BioSpace: Meissa's Intranasal COVID-19 Vaccine Shows Promise in Non-Human Primates

MedCity News: Meissa Vaccines’ Leg up in the Covid-19 Vaccines Chase Goes through the Nose

Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

Big4Bio Podcast: How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine

Big4Bio: Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV

Big4Bio: Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges

Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

BioPharm International: Modernizing Intranasal Live Attenuated Vaccines

Biotech 2050 Podcast: An End Game Vaccine for COVID-19

Meissa Vaccines Appoints Dr. Michael Watson to Board of Directors

BioSpace: Meissa’s Intranasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses

Meissa Announces IND Clearance for Phase 1 Study of COVID-19 Intranasal Live Attenuated Vaccine

Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Candidates

Covid Vaccine Player Emerges on the Peninsula with Hopes of Starting Clinical Trial Early Next Year

BioSpace: Another COVID-19 Vaccine Joins the Race – This Time, it’s a Live, Weakened Virus

Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine

Meissa Vaccines Closes $30 Million Financing to Advance RSV Vaccine into Clinical Trials

Endpoints: Meissa Obtains $30M Series A to Test Synthetic Biology Approach to 'Elusive' RSV Vaccines